In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Effectiveness of early administration of Tolvaptan for cardiac prognosis in acute decompensated heart failure

Session Poster Session 3

Speaker Toshio Kaneda

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : T Kaneda (Yokohama,JP), M Suzuki (Yokohama,JP), K Hara (Yokohama,JP), M Omori (Yokohama,JP), Y Taomoto (Yokohama,JP), M Iya (Yokohama,JP), Y Yamakami (Yokohama,JP), H Shimada (Yokohama,JP), T Manno (Yokohama,JP), A Isshiki (Yokohama,JP), S Kimura (Yokohama,JP), M Shimizu (Yokohama,JP), H Fujii (Yokohama,JP)

Authors:
T Kaneda1 , M Suzuki1 , K Hara1 , M Omori1 , Y Taomoto1 , M Iya1 , Y Yamakami1 , H Shimada1 , T Manno1 , A Isshiki1 , S Kimura1 , M Shimizu1 , H Fujii1 , 1Yokohama Minami Kyosai Hospital, Cardiology - Yokohama - Japan ,

Citation:

Backgrounds: Tolvaptan is recognized to have effects on acute decompensated heart failure (ADHF). However, the prognostic value of the timing of Tolvaptan administration in hospitalization was not elucidated.

Methods: We enrolled consecutive 155 patients with ADHF (81.7±10.5 years, 83 males) who took Tolvaptan treatment in hospitalization, and observed them for max 60 days retrospectively. The patients were assigned into two groups: patients taking Tolvaptan within 48 hours or over after hospitalization (Early group vs Non-early group). Cardiac death was set as primary endpoint.

Results: Twenty-one patients died for observation period. The mortality rate was better in Early groups (Early:3, Non-early:10, P=0.002). Multivariate Cox regression analysis showed the early administration was a significant negative predictor of cardiac death (hazard ratio:0.237, P=0.029). Kaplan-Meier curve analysis revealed the survival curve was significantly better in Early group (log rank P=0.018)

Conclusion: Early administration (within 48 hours) of Tolvaptan after hospitalization was a significant negative predictor of cardiac death in patients with ADHF.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are